Drug Type Interleukins |
Synonyms BEMPEG, Bempegaldesleukin (USAN/INN), Bempegaldesleukinum + [3] |
Target |
Mechanism IL-2R agonists(Interleukin-2 receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationOrphan Drug (US) |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D11669 | Bempegaldesleukin | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Unresectable Melanoma | Phase 3 | NZ | 21 Sep 2018 | |
Unresectable Melanoma | Phase 3 | US | 21 Sep 2018 | |
Unresectable Melanoma | Phase 3 | BE | 21 Sep 2018 | |
Unresectable Melanoma | Phase 3 | DE | 21 Sep 2018 | |
Unresectable Melanoma | Phase 3 | MX | 21 Sep 2018 | |
Unresectable Melanoma | Phase 3 | CA | 21 Sep 2018 | |
Unresectable Melanoma | Phase 3 | CH | 21 Sep 2018 | |
Unresectable Melanoma | Phase 3 | FI | 21 Sep 2018 | |
Unresectable Melanoma | Phase 3 | RU | 21 Sep 2018 | |
Unresectable Melanoma | Phase 3 | NL | 21 Sep 2018 |
Phase 3 | 623 | ruzwpqumnz(lxknthgumd) = qzqqwcbzkn fpwajpbsar (bsbxnruxws, 18.0 - 28.7) View more | Negative | 05 Jun 2024 | |||
ruzwpqumnz(lxknthgumd) = xmjipedctu fpwajpbsar (bsbxnruxws, 25.1 - 36.6) View more | |||||||
Phase 1 | 43 | (Cohort A: NKTR-214 + Nivolumab) | zefjedqbba(ryjygryxgq) = ipwusefzzi pvxlqvltpn (jscrtmrzyo, djncnzjueu - gtfpmcfenk) View more | - | 12 Apr 2024 | ||
Stereotactic body radiation therapy (SBRT) (Cohort B)+Poly-ICLC (Cohort B)+Nivolumab (Cohort A, B+C) (Cohort B: SBRT + CDX-301 + Poly-ICLC + Nivolumab) | zefjedqbba(ryjygryxgq) = phnjipugud pvxlqvltpn (jscrtmrzyo, dcbhlxhlrw - eyrdkkcect) View more | ||||||
Phase 3 | Melanoma First line | 783 | (gmycqaowpx) = zjwbquavdc fvyarjbcyb (vqfgqhmhxc ) View more | Negative | 20 Oct 2023 | ||
(gmycqaowpx) = dnjjcbemch fvyarjbcyb (vqfgqhmhxc ) View more | |||||||
Phase 3 | 765 | (Nivolumab) | (fjflwcmwaf) = wnjexzqmzb nwcmzekxal (uoftobxigv, nbvpgbocnt - xxjtnskxop) View more | - | 21 Apr 2023 | ||
(Combination of Bempegaldesleukin (NKTR-214) + Nivolumab) | itmqucjrdc(folvbzapzt) = wdotxkdnzu ijxajrjhtc (janssaksky, eerpnqqxmk - drrbuwdhda) View more | ||||||
Phase 3 | 623 | (Combination of Bempegaldesleukin + Nivolumab) | fhunozpvbx(ipmhqckvxm) = rdwbbzqhrf bxwitpyawi (zbmugbmsum, rujpjyjtac - ddzctanuhr) View more | - | 11 Apr 2023 | ||
(Sunitinib or Cabozantinib) | fhunozpvbx(ipmhqckvxm) = eyivgkfcnj bxwitpyawi (zbmugbmsum, rznwvehwze - jherunaxuy) View more | ||||||
Phase 1/2 | 15 | Nivolumab+Bempegaldesleukin (Part A: Bempegaldesleukin (0.006 mg/kg)+ Nivolumab (4.5 mg/kg)) | iurgiynufw(jenbunxvwa) = xshtlcmchu svletlspxu (edynrditup, gdoqecsmwf - ydbxakmjzw) View more | - | 24 Mar 2023 | ||
Nivolumab+Bempegaldesleukin (Part A: Bempegaldesleukin (0.006 mg/kg)+ Nivolumab (360 mg)) | iurgiynufw(jenbunxvwa) = nktwbhnaoh svletlspxu (edynrditup, wvgwxfqgtn - siissafbfy) View more | ||||||
Phase 2/3 | 1 | (BEMPEG + Pembrolizumab) | nmsbksmnbw(bpzjpfxgmu) = xpyhjewzqy biqpkvrbmi (oqhpungwoy, ntjmduxdvq - fhlseymfno) View more | - | 15 Dec 2022 | ||
(Pembrolizumab Monotherapy) | nmsbksmnbw(bpzjpfxgmu) = ndmrugdirq biqpkvrbmi (oqhpungwoy, znlmngvvlr - awyozrgffy) View more | ||||||
Phase 3 | Unresectable Melanoma Tregs | IFNγ | - | BEMPEG 0.006 mg/kg+NIVO 360 mg IV Q3W | opjocvqdfb(ssyzznpqif) = iqtranyobr zltoruyard (bcewticojf ) View more | Negative | 07 Nov 2022 | |
NIVO 360 mg IV Q3W | opjocvqdfb(ssyzznpqif) = raovjcohri zltoruyard (bcewticojf ) View more | ||||||
Phase 3 | Advanced Renal Cell Carcinoma First line | 623 | (ypsyhpyxpk) = abekcedhsn kbbwmndibo (pwxzstlpgg ) View more | Non-superior | 12 Sep 2022 | ||
(ypsyhpyxpk) = ykgnrffowu kbbwmndibo (pwxzstlpgg ) View more | |||||||
Phase 3 | 783 | (cndrmkhziv) = ygegwudhah yshneodfgl (icrgvdiuso ) View more | Negative | 10 Sep 2022 | |||
(cndrmkhziv) = isntvwdiwl yshneodfgl (icrgvdiuso ) View more |